Ras Mutation Screening Panel

Available Products

Product Name/Description
No. of Reactions*
Product Code
RAS Mutation Screening Panel
50
RAS-RT50

*Includes all controls

 

RAS Mutations and Cancer

KRAS and NRAS are members of the RAS family of GTPases that play a central role in the MAPK signaling pathway. Activating mutations in exon 2 (codon 12/13), exon 3 (codon 59/61), and exon 4 (codon 117/146) have been found in various cancers, including metastatic colorectal cancer. Recent clinical studies using anti-EGFR targeted therapies of patients diagnosed with colorectal cancer have demonstrated that tumors possessing KRAS and NRAS mutations are less likely to respond to such therapies than those without mutations (Clin Cancer Res 2013;19:1902-1912).

Kit Features

The RAS Mutation Screening Panel detects somatic mutations found in exons 2, 3, and 4 of KRAS and NRAS genes. Below is a list of mutations detected by this kit.

Gene Mutation Group
KRAS G12A, G12D, G12R, G12V, G13D 1
G12C, G12S 2
Q61H, Q61L, Q61R, A59E, A59G, A59T 3
K117N, K117R, K117E 4
A146T, A146P, A146V 5
NRAS G12D, G12C, G12S, G13R, G13V, K117R 6
Q61H, Q61L, Q61K, Q61R 7
A59D, A59T, A146T 8

The RAS Mutation Screening Panel is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers in a multiplex reaction to identify the presence of the mutations in a total of 8 reactions per sample. The test does not distinguish between mutations within each group.

The testing procedure involves three (3) simple steps:

  • Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fresh frozen tumors
  • Amplification of regions of the RAS genes using allele-specific primers.
  • Detection of amplification product on a Real-Time PCR instrument.

This test can be completed in approximately 2 hours from isolation of DNA to test result.

 

Equipment and Materials

EntroGen’s RAS mutation screening panel requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes.

This test includes reagents required for PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.

Intended Use

USA:

EntroGen’s RAS mutation screening panel is provided for research use only (RUO). Not for use in diagnostic procedures.

Europe:

EntroGen’s RAS mutation screening panel is available for research (RUO) and diagnostic (CE-IVD) purposes.

 

Bibliography of studies using this product

Cetuximab in Treatment of Metastatic Colorectal Cancer: Final Survival Analyses and Extended RAS Data from the NORDIC-VII Study. Guren, Thomsen, Kure, Sorbye, Glimelius, Pfeiffer, Österlund, Sigurdsson, Lothe, Dalsgaard, Skovlund, Christoffersen, Tveit. Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. Br J Cancer. 2017 May 9;116(10):1271-1278. Pubmed ID 28399112